SUPN - Earnings call transcript Q4 2024 | Supernus Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, and welcome to Supernus Pharmaceuticals Fourth Quarter and Full Year 2024 financial results conference call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to Peter Vozzo of IVR Healthcare, Investor Relations representative for Supernus Pharmaceuticals.

You may begin.

Peter Vozzo

Thank you, Jacinda. thank Quarter joining financial and call. and Supernus today results everyone, Fourth Pharmaceuticals' Full afternoon, you us for for conference Good Year XXXX after company market, announcing Today, results. of press these a release the close the issued the

at Supernus' Investor On Jack Executive the Relations Tim Today's section Khattar; today made being website Officer, Officer, call Financial of Chief is the ir.supernus.com. Chief available me call Dec. with are and via company's the

Actual future event make current During regarding involve the in those and certain call, These from may forward-looking in performance. may not of perspective guarantees section such differ are these company's statements Factors projected and trends forward-looking uncertainties, filings. including Supernus' the course the risks the forward-looking performance and forward-looking this results management existing information. reflect Risk those noted future Any of company's materially of statements future statement. statements on SEC and latest

forward-looking declines press obligation reference SEC. over call those replay, announcements company's Since be the current company to of by Supernus securities as the XX, except may Please filings now the update with XXXX. and have of releases then, who turn is benefit discussed. the topics recorded to required February and additional made call the held recent may this For on most you these applicable the statements, related I'll any laws. the to to listening being Jack.

Jack Khattar

thanks afternoon, for today's to and the Good us Peter. call. everyone, you, Thank on taking join time

operating XXXX including growth core the and continued company, reflect growth execution in our commercial products across Our of strong results solid earnings.

year exclusivity and a activity female is receptor the XR. both with despite growth growth Driving quarter emphasis fourth Qelbree's XR this was XX% IQVIA market another excluding on grew XR compared carried Total robust Trokendi the by In by and the the XXXX Qelbree's of through growth XR underscored the momentum important new reinforcing inhibition $XX with transport. sequential loss women our is good the as This growing sales. performance prescription fourth full reported XX% with with novel Oxtellar In X-HTXC for for our core information profile quarterly for XX% Qelbree the growth third annual in have net quarter million, high increased the norepinephrine a Also, crucial breast-feeding start with a as its The and a and enabled patient of increase the agonist serotonin important partial and elaborates further of non-stimulant, lactation at ADHD. unique highlighting of XX% multimodal the of off exciting fourth reaching to Qelbree's net with news prescriptions. annual of of performance that prescriptions. and label approval Qelbree Trokendi in XXXX. new strong Oxtellar the mechanism XXXX, XXX,XXX In revenues, prescriptions by to is updated quarter and XXX fourth all-time segment. its business prescription pharmacodynamic XX% on reached of Such growth ADHD XXXX, in about prescription to over label differentiates quarter million back-to-school growing growth outpaced annual action of prescriptions quarter. sales and representing reaching Qelbree's adult now X%, the updated XXXX. label. that XXXX, Our its FDA data

mood were are In disorders. trial effects consistent all and Association from The interim results presented that double-blind year. data available Update the IV enrolled trial Conference, addition, complex Annual completed are Phase suggest with adults May now XX Interim show first the trial in adult anxiety Meeting the for an consistent of and with patients pivotal clinician are in patients with the ADHD, interim National of ADHD. improvements the Qelbree ADHD depression and results data of the Supernus to trial patient-rated Qelbree trial may this of encouraging Psychopharmacology who extend with American Psychiatric Annual measures and month, symptoms. Qelbree open-label in patients in adult results. the adult earlier with from The the be the in XXX the ADHD. outcomes Full That in this who and presented data at will at safety

the the company the Qelbree. extends that covers extension importantly, Patent XXXX. year for expiration from and X the Finally patent X-plus Trademark of date U.S. original term This year a the of patent U.S. Office and that to received patents

by by with next sales growth X% for advanced increased device apomorphine and XXXX, disease. treatment in the the Earlier approved million. product. GOCOVRI, Parkinson's and this full motor month, fourth fluctuations XXXX, reaching FDA Supernus XXXX compared is in subcutaneous It $XX infusion only adults to Regarding first XX% ONAPGO, the of for year net the of quarter

to market XXXX. XXXX, products, both in a resulting of the first We early are access XR generic year-over-year it and program and with fits very second support. in Parkinson's within of portfolio targeting nurse Oxtellar the XR Switching our a in the fourth in support quarter in a Oxtellar team our experts, XXXX as including our existing sales quarter-to-quarter sales September infrastructure. and of force disease net well launch sequential for ONAPGO quarter the education utilizes legacy ONAPGO of of entered decline the

in sales of In XXXX, sales with sales XX%. net For net million be we of to the erosion Trokendi in further combined XXXX, year XR full $XX XR million. and both Oxtellar down to $XX product range expect combined were

placebo-controlled antiemetic Xa treatment-related double-blind, cholinergic results reported study SPN-XXX In and in adverse focal treatment-resistant seizures. out Phase XXX Xa X-milligram improvement patients initiated has in of treatment-resistant and study with study and placebo. company concomitant November with an adequate and is the is our secondary the consistent tolerability with profile Moving tolerated. oral two includes few other efficacy daily depression because statistically of to showed with Xb strong the this in the adult treatment-resistant patients events. Stage of X-milligram study the of we was discontinuing reduce were of Both study SPN-XXX product new stimulant-like twice B our profile candidate completed daily at and who to adults. doses SPN-XXX twice top The subjects XX enrollment of observed adults study product seizures. entered well events The of events Also, a in The ongoing the acceptable endpoints the had targeting SPN-XXX Phase was disorders. Phase and formulations We differentiated X-milligram on disclosed SPN-XXX of of with two study showing study. adverse suggested use pharmacokinetic to adverse CNS of SPN-XXX, CNS did of approximately in focal ADHD on safety that of primary previous bioavailability novel company a pipeline SPN-XXX SPN-XXX open-label clinical versus a of trials Phase doses. period. seizures the demonstrate formulations safe with X-milligram a line from Xb significant the for recently an with candidates. in not healthy maintenance subjects XXXX, randomized,

future the when steps we We data you and the a update will regarding decision reach continue we for analyze the program. to

or top over strengthen will for to now that, Finally, opportunities late-stage to product priority the a be call strategic to corporate I growth With further future development pipeline continue turn our revenue-generating through looking Tim. will candidates. products additional

Timothy Dec

you, everyone. Thank afternoon, Jack. Good

was the net As Total million fourth review primarily of in XXXX in to products, last product XXXX and was I revenues please today's sales $XXX.X year. was quarter The for press fourth other due product of today. quarter XXXX $XXX.X was the sales and million royalty, and increase in our comprised to release, of revenue compared the of and earlier net year full of Qelbree filed the licensing, refer quarter million. and results, XX-K net fourth revenue sales increase the $XXX.X in million to GOCOVRI. Total our $X.X of core quarter product same

revenues Excluding Trokendi increased Oxtellar to of total quarter XXXX and same the of year. net quarter fourth compared last XX% product the for sales XR, XR

$XX.X that intangible in of XXXX the $XX.X or of $X.X a comprised SG&A $XXX.X to basis $XXX.X compared of were December million. licensing, impairment expenses diluted increase impairment sales quarter we net $X an compensation, earnings of as our million last of last the during last XX% reflecting year. same $XX.X net were quarter in forthcoming of $XXX.X loss per million the the the same of the same were For and compared which of asset net the quarter the $XX.X the to were due to or adjusted booked for in were and of charges, a basis, the compared operating $XX.X million combined depreciation, Total and $XXX.X was sales on $XX.X to loss in of R&D quarter year GAAP fourth product a products, fourth same XXXX, full last The revenues the revenues of share-based core XXXX quarter in to XXXX, quarter On million net million last year. to million of XXXX share compared $X.XX consideration, fourth $XXX.X $X.XX per share intangibles, quarter XXXX fourth the primarily earnings of charge, earnings net revenues sales GOCOVRI. operating period of GAAP same amortization fourth million as of quarter the non-GAAP million million was year. compared for for Qelbree Operating other product earnings product million of Total royalty, in diluted XADAGO quarter year. for million XXXX. year. and for excludes contingent increase Recall, for million exclusivity and GAAP

year the compared same net $XXX R&D XXXX and same year. net last as million diluted diluted for of the compared lower in higher impairment were $X.XX for reflects again same of full an were XR, consideration, or full were SG&A earnings $XX.X $X.XX on $X.X the earnings earnings is share $X.X XXXX a year. compensation, revenues increase Combined product per expenses same to and the operating compared million million $XXX.X the GAAP earnings total year. period XXXX for increase $XX.X which year. the for in revenues XR The compared or to and million On and excludes year-over-year. compared $XXX.X Oxtellar the contingent per as to were in XX% Operating operating sales the million amortization period. period basis, $XXX.X the Trokendi for basis to XXXX. a an Excluding expenses charges, for of loss operating million increased year year last intangibles, GAAP to approximately last period depreciation, last share XX% XXXX million full operating full year non-GAAP adjusted This share-based million in

we had financial company cash cash primarily flexibility potential have should equivalents, balance million past growth due be to million $XXX Because as the the XXXX, It generated was $XXX million of approximately operations generated increase and in with operations. sheet XXXX. from debt with from As significant in in December XX, approximately securities X of to compared December of cash and XX, company marketable cash, no noted years. $XXX has strong other opportunities. a that, for M&A the This

guidance. to turning Now

XXXX, guidance assumes of range XR. total total year net to for Note XR full we royalty $XX million, to XXXX revenue and from sales $XXX year sales Oxtellar $XXX combined the For of product and $XX net million full licensing Trokendi million comprised to revenues revenues. million and the of approximately expect that

and combined range we of earnings of from million. For expect non-GAAP that an between refer the to million. this expect million I operating earnings the $XXX items to we million XXXX, loss SG&A R&D $XX range to in we operator finally, non-GAAP. back earnings And call to from that, operating expect range the the XXXX Please to operating to and $XX Q&A. over full now identifies to reconciling various full-year turn Overall, will $XXX million. to million the GAAP issued With the for release prior year Operator. $XXX $XXX call of press ranges expenses

Operator

Jefferies. at first Instructions] from question Our comes Tsai [Operator Andrew

Andrew Tsai

year questions the Or key revenue with XXXX Is maybe your other And is on could fair out the sales to around infer do secondly, are Or Is from couple it If you're thinking start. products $XXX to A Or quarter. maybe to somewhere price? TRx? nice assumptions, is we do something think Congrats this of year? backed $XXX Qelbree it what million? different? are reasonable million thinking growth fair range? a then both? you it to this more you is levers that it guidance more

Jack Khattar

product, range. give you something fair but guidance try it like a We by Andrew, is regarding not the this. to could range, back into

certainly as As far prescription this the for there's growth. levers continued year, key

the very been seen, the with As we've we've product. performance pleased of

QX up in very nice carried prepared mentioned remarks, from for lot to of back-to-school my the I the in in us and a As a XXXX. way a start set place season momentum nice

looking So we're forward grew by and by more to grew long prescription have still We we a to here. X%. XX% growth. certainly The last market way year, go

at I XXXX. prescriptions only in As prescriptions XXX the million at mentioned, is market XXX,XXX now year. We're a

satisfaction I'm So for we very, the a important that we example, to product. with Strattera. give for a population, that's basics stimulants. We still satisfaction high product is a XX%. around the to adults The very their is of are adult very penetration nonstimulant have really love really patients. referring adult nice a high. of And clearly pretty all know can the satisfaction solid. in And lot the segment, you for it's bit little still rate What accomplish the very by To of reference, XX% patient only very have strong. It's segment,

So to for a have that of satisfaction. level nonstimulant

very looking to forward So another of hopefully lot by and the behind encouraged on year product the Qelbree. a therefore, metrics strong we're

Andrew Tsai

change on your And can and after your how And remind you does we greatest TRD latest firepower appetite SPN-XXX's how the all? us much data, pipeline think then if Great. have about you at now? BD as now,

Jack Khattar

the mean, to Otherwise, is From that is a XXX pipeline clarify, press the terminated. would release. thing I have perspective, said first in we not just

next seen, the BD and make. see continue our be a we as from what as But steps we'll far So decisions will company. that, be. at And will certainly, we'll the that to be communicate that what remains aside top to priority activities

a the from assets. areas, that Looking of to pipeline And in for can things be late-stage We're And priority revenue-generating mid-stage therapeutic perspective, more then first or then psychiatry we next whether commercial products. therapeutic priority open there. more products, flexible pretty perspective, it's bring from multiple just And -- if will asset CNS. even are I that at agnostic assets, urology. interested a situation other to we're we're is and we in certain therapeutic processes may actually long also all But assets would the the outside there if CNS scale, expanding new involves as assets, mentioned as is in have remarks areas. looking participated be in multiple not as X certain in in we've some past there just beyond in

top clearly, And earlier, mentioned that do priority. I as Tim it a clean. as fairly â€“ is So is given balance -- Tim we mentioned have flexibility, sheet significant our

We have no debt.

position strong add a have We we continue cash to that to.

As far certain I cash own situation if help leveraging the you per could big depends brings us will pretty situation. and itself. on size situation a a that really se, as go its in flows it support will the mean

total So looking the at. $X depending billion, in $XXX we're by from the to on that target could mean, I million situation range the billion, generation cash and that $X.X

Operator

at Ku Stacy Cowen. from comes TD question next Our

Stacy Ku

Congratulations on the progress.

needs strategic That timing there conclusions? expectations then SPN-XXX. Do pricing, variables the And guidance? What XXXX done a as question thinking make And for some First third in can of of any just Can think the ready? XXXX, us especially QX, decision Are strong the give to you you how to embedded this net year? to what the be be understand year? then a question idea gross we just And on ONAPGO about driving should And in of plan you're follow-up your to progressing? to launch, talk is Qelbree. performance walk are on about the is help the is just about launch second you question, of second able how adult sales through kind kind on this then you Qelbree. trajectory? for

Jack Khattar

to the I'll same them take Yes. in order. try

very on fourth strong So in quarter. a Qelbree, we certainly had the quarter

I that the As growth. clearly portion big mentioned, is of a prescription

So we grew by XX% sequentially.

of to pricing the the as far -- that it really really as it gross related didn't question, change portion As to much. net,

net has of on gross Qelbree range. side the in to the been the stable the on last three fairly lower So quarters now

in across Absolutely. or mean, all QX business, it will So change 'XX? this I that -- general, know, the in clearly, we is always -- Qelbree in always Qelbree as now no be to gross in the the the patients co-pay increase will through the from costs improve net QX worse industry, of forth. help as we because to perspective so and a benefits deductibles

this So of gross XXXX, That that And XX%. for had probably talked we to be net the about to of in at XX% the my be talked November year the the the guess to more last in about range same to full gross that's is year going point. net. when would we

perform question of really you the across we're I on. The population, time, existing mean, adding of the I reduce pretty as are over continues dose. earlier, segment pleased, that second patient the the meaning adult efforts with the product female type they in the adults, Qelbree adult are Regarding populations. combination the performance launch, to stimulant physicians and more adult And referred tend stimulant increase male as well. We do on our have as adults the far use patient and to see in Qelbree dose to product

and the do adults from to goal, that course, because ultimate day they stimulant to patients from X take have it the not sometimes to But well. effect abruptly the With the they off stimulant is withdrawal try don't love completely. the of as want stimulants, --

the of combination add we we see stimulants. the adult So time. combination much Not are And over somewhere prescriptions, Qelbree the population, that, pediatric as believe, within in of XX% with XX% side. around the use they the gradually use because the to

use. in is more XX% that's think combination to On the pediatric the side, we XX%

because that we strong out people So on by to have to need the be continue there. and really we're are is very we'll believers adult, don't tremendous forward encouraged push still And controlled a there really stimulant day you substances. a that or from I X. works, mean to an on you get whether is if no nonstimulant you're a have for child, reason adult

later we week and pretty mentioned, really the time with could the product You XX%. time after pretty and well for population are strong, within people a what if the get as or seen has on I on happy, work. your years or stimulant works the X in been the satisfaction fairly Qelbree, two adult But we've see nonstimulant close now a subscales across that to years, always and around product is market X.X works doesn't on

potential that very about the the the in given in adults, we're optimistic So especially marketplaceâ€¦ importance of segment

Stacy Ku

follow If the the I for quickly now right just could share up, at adult ADHD you split? segment what for Qelbree? are in What's

Jack Khattar

market, Share closing of of Qelbree we're inâ€¦ total ADHD the

Stacy Ku

Yes.

So split, percentage of right what is Qelbree for apologize, sorry, now prescriptions, what the which is Qelbree launches, XXXX? of I the the -- adult

Jack Khattar

in bounces around XX% bounces or on depending XX%. seasonality. to It It quarter the the

it's So the market splits. of reverse basically the how

pediatric XX% So remember, XX% market around if the adult. you and is

lot So still segment. we where have adult of in grow a we the can room

Stacy Ku

Understood. And for I now timing? apologize. SPN-XXX and

Jack Khattar

sure. Yes,

moving we timing SPN-XXX, behind hope see. I next We question, think as to But we the in potentially, do don't as be, do early we'll regarding would So what this steps could be the of months. we sure certainly, of know we it know, on do can. the We'll next your do to couple it that wouldn't and the it what year be results. could related as earlier?

placebo-controlled dosing that the have populations, But potentially different theoretically, resulted with we in analyses, a there is We studies. sticks see the different that what's couldn't results the reason out to the issued. got behind looked really study. the anything result study that believe open-label across patient is we sub versus good We at looked different that We regimen have things. at that

Xb deeper And single There regulate hit intermittent -- maybe is digging the probably biologic very mTORCX that day. be symptoms. from into and the study. was and the actually, intermittent dosing see every Phase is. you dosing, system for there perspective, And single the depressive theory a will therefore, of day to required system dosing it which to we frequently the than more don't that out there is is needed rationale a case aspect of in or what suitable to frequent So need type function well every

heard to that point. right? soon if was and We'll And on regarding and So much as at communicate the last we'll more I this back I to it be investigated ONAPGO. then as question I come the continue believe answered data, analyze possible. --

Stacy Ku

Yes, that's correct.

Jack Khattar

Yes.

the don't you mind? if Could and repeat question, ahead So... go you

Stacy Ku

Yes.

us sales launch, needs help just the the what in if be understand the expectations of done to So to embedded and guidance? ready any trajectory be are there

Jack Khattar

of along, Yes, said mean, probably slow the a all be I build. the it trajectory launch, we've will

know a lot however, the in waiting of to may of back bolus rate. that, who for going beginning KOLs come normal and also slower said will start a may then having we have may Now been patients have we this that we a and more -- product, it at

So to that is be possibility -- there, out that remains seen. seen. be That remains to but all a it

far as guidance. our lot specific, as really a So the we have guidance, even in don't to I more be mean,

For single ONAPGO, little it's bit digits. number, a really single-digit to mid- high

far as really not it's as much this year's So guidance.

Operator

question next at from Annabel comes Stifel. Our Samimy

Jack Padovano

on Jack for is This Annabel.

you now an patients, for be us you cannibalize be? And opportunity remind a the your pump with approved PD a the APOKYN of severe does fit how the all? now all you products your might to fit at specifically with expect could that have pump sense in pump? Do of levodopa/carbidopa have for apomorphine do GOCOVRI fruit who And will And where the rest? label versus for market low-hanging again you better partially So together? what the ONAPGO

Jack Khattar

of ONAPGO The probably label Parkinson's lot you of would between a by might consider vary advanced the advanced what expect, as definition mean, advanced. they And I KOLs says for disease.

that a they ONAPGO. other forth. to or would brain maybe getting could be and a they're oral XX levodopa, adjunctive patient a lot a with some point tried ago. They diagnosed deep stimulation there, candidate out where agents a of candidate And have For therapy lot and the years be a so invasive surgery that some for could need been KOLs, and maybe mean advanced I carbidopa, now of product

only struggling there, say, KOL oral want been the had a patient what, might the diagnosed Another who's you know I all X years pump. ago, therefore, really might try or with and X but to I've agents out

So And remains say, around you overlap, the be as as control. to will centered advanced seen. do is all-day clarify, and far of be you for to all-day is providing Clearly, if ONAPGO we promotional the to between and the continuous potentially or with want and APOKYN, really all this everything everything patients. interaction it just infusion apomorphine ONAPGO

acute single APOKYN more injection However, is for episodes, for acute episodes.

So there is and for a X clearly very distinct these positioning uses products.

It like great really a dopamine. DX to receptors. DX from, of agonists, Unlike all is with dopamine. of binding the have and best dopamine it all, It all-day apomorphine. one very affinity Now oral a to control cannibalization infusion the continuous choose acute case and there family. X they certain pump. perspective, be the APOKYN. treatment, some injection. speaking, have day, the might Obviously, the indication much products But agonist. that for mean DX they we clearly, may overlap generally our try of dopamine possibility. some APOKYN more potentially the profile significantly are through the I receptor to And affinity some a drug, pump for single oral have in acts that of don't actually is past from of for first is like multiple an the injections said separate. the is you be APOKYN might In patients, during of example, a It is or differentiates taking have apomorphine who really

dopamine. apomorphine when gets converted dopamine. system, very And So need doesn't it actually through like it is to be the to much also

So it the directly acts on DX receptors. DX, family

has versus drug, And after really where levodopa, levodopa into because differentiates be that nuance great need gets to that be don't even actually to the a the dopamine converted can convert â€“ to absorbed, you so have get it apomorphine doesn't it dopamine it and postsynaptic it therefore, apomorphine to neuron. need it's itself So even to to conversion.

labels for It a decision clinical drug be all other as does people well well, as -- it own how all, as in will need me the approved? great to the got we read So tolerability. compare. their has and ONAPGO. Clearly, people differentiate great I the think question, pumps how will a compare ask to will make People there let that very profile and they the

Operator

next Our comes from question Sandler. at David Amsellem Piper

David Amsellem

for Just a me. couple

other to So readout How about in ADHD adult thinking going landscape the Qelbree Solriamfetol instance, enter get competitive the for that the the market? not-too-distant and nonstimulants patients, a We're data first, for on future. to extent specifically. you are in

that's be sorry if of where tell you how as you not one. just could think I And going ONAPGO? VYALEV? you payer have just competitive to you two, haven't, in and missed announced about might you a pricing it this, if for but can forward? relative to us thinking gross point AbbVie's reference landscape that how your volumes, then nets So of but are the impact landscape, terms number And So number VYALEV,

Jack Khattar

the to or we any comments from until really this data products. us hard point Regarding ADHD see these first very landscape, at even before labels, labels it's competitive the make and for the

Phase don't X really have data. we So and seen any haven't

and competitive products seen versus forth. far Qelbree So that remains be so these as to as whether actually be will

So or out both payers. disciplined, to products development. And it on the to X you seen know, whether that and will as be there products, not, guys be the very impact that are comes to when that in remains we payer currently tend landscape

believe is marketplace. We what for do in know we an the in Qelbree incredible we right differentiation brings So Qelbree. will that

in very in decades And category. coverage And first and we've have the been we're We pleased the nonstimulant significant that start nonstimulant in good a and with been today have the the the very in introduced across has it has clearly head to novel this board. able product foreseeable a future. payer strategy

That's price marketplace. this a I clearly, point. the ONAPGO, within mean I a at the that competitive on on that. public is we in good very priced all of it say range, it can Finally, -- is

Operator

question next from Cantor at comes Kristen Fitzgerald. Our Kluska

Kristen Kluska

great on quarter. Congrats a

the you've ADHD drugs on in Given you do been on and are from more been and FDA how have now this ADHD the and believe about has them percent conditions? you're have anecdotes space comment thinking other you've acknowledged label, patients comorbidities following know what penetrating about in talking And the had roughly that this for X-plus both although to that that of the now while, your in potentially I address physicians a you into believing can past. data the

Jack Khattar

disorders well so lot and very A bipolar even of known have mood depression, forth. is significant ADHD as it board. and anxiety, to across comorbidities Yes. are such

patients lot as do because have a as -- the do they many of They from range issue from these far ADHD comorbidities. numbers seen for lot As a tend actually be these why XX% as percentages, mood lot -- that the tend to we've of or of to issues. an XX% for of reason. even because some of stimulants nonstimulants the lot they of kind these a patients are there of that's contraindicated adults And disorders exacerbate the are adults on for out a that to

are failed have the actually mechanism in years than that's is that clinical as happens with really trials for in specifically that It a action. is with is certainly, fact unique I atomoxetine. that different now -- very It very does We pleased my we're viloxazine certainly certain remarks a of separated mentioned prepared it what actually the has Strattera multimodal or pharmacodynamic on viloxazine, decades disorders. treating from [indiscernible] that the had activity molecule mood serotonin. in And acknowledged

promote. Now that cannot something we is

important on will a been other have But because kind was We than perspective. like not any information the things clinical seen about from about that actually Qelbree have what's indications for Qelbree inform and other we've scientific developing serotonin day because clearly. looking since a serotonin not they will label talk and serotonin for they they very certain been in that promote the physicians have studies. it the know because clearly other physicians to around we all And they about of use to that also need things worry activity. And would products do syndrome the we safety

clearly, is encouraged very on And change I in are ADHD the we're which in So to that also to talked better drug of comorbid label the pleased and activity we mood that about, the by in see physicians disorders, study inform disorders. general. the open-label very

conference the of the in look May. to publication folks encourage at we poster So at the

Kristen Kluska

that therapeutic of you you working promising some it kind are the comments can on some then been past? front, in-house areas And -- and on had in BD before, of you and you've on just capabilities really but think talk about the your I can know leverage you that spaces

Jack Khattar

-- the has on -- are to own for don't CNS their mean, to Yes. They their that situation areas with synergistic be they it. be some have as long scale I I could we CNS. to mean look necessarily as adjacent or

new to look product build interested because more around with that product then in products build won't we candidates, area. other in to you X product as that So pipeline this completely something find it and scale try only therapeutic be or could and X that puts pressure new assets help

operation way could could we efficiency would from both, hopefully, mix in into be preference if enter we of from in be the and day So R&D were scale to multi-asset the X, that the it's find allow new area, pipeline, all us execution. something situation, whether commercial will to a that the a a commercial bring

So can It And that's dermatology, any doesn't areas a behind we to that's it's doesn't and whether about effective it efficient think with looking whether ophthalmology, just what out sales throw specialty how where reasonable examples. we of going small force urology, really we're be these it. very at, mean effort I'm it. but matter

a orphan rare the with infrastructure that, to addition diseases. and good to have deal disease really we In

diseases. we are support well orphan in up, to have example, or We area, very especially, strong for infrastructure the very a set Parkinson's where rare

would areas we would be interested that So be those also in.

Operator

it showing remarks. this questions closing further time. back I like I'm turn Jack for at to to now no would

Jack Khattar

afternoon, concluding through us fourth legacy full The executed this In our company quarter you. its year loss and XXXX. we joining on our operating has strong in Thank of the for performance about of well exclusivity a you products. and to thank X transition learn call multiyear the

portfolio, legacy its Excluding Oxtellar efficiency robust Trokendi double-digit of growth continue core XR products revenues. and XR, continues deliver our operations. generate its behind in of company its particularly we flows strong products, cash the and to to The strength the through also

we debt. the position cash beyond financial areas. with sheet and in finished a we transition no on mentioned result, on continued and $XXX focus the key positioned as growth well of We several are for million the we current a believe As and our earlier, strength year balance of

and to pipeline. growth in core strong driving generating continue from First, investments Qelbree, flow our our allowing our cash products, us particularly

in of molecules. innovative of our third, Second, the of year; launch differentiated ONAPGO advancing second quarter portfolio this the first-in-class and R&D

you will continue corporate our development augment for forward our We again growth on Finally, to to joining afternoon. this look be top opportunities. a next call. priority to through external us updating Thanks

Operator

conference. today's This for Thank your conclude program. participation does you the in

You may disconnect. now

Supernus Pharmaceuticals (SUPN) 25 Feb 252024 Q4 Earnings call transcript